CIK 0001130598
- Non-accelerated filer
- Smaller reporting company
Traws Pharma, Inc.
Sign in to watch- Ticker
- TRAW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 267-759-3680
- Business address
- 12 PENNS TRAIL, NEWTOWN, PA, 18940
- Former names
- Onconova Therapeutics, Inc., ONCONOVA THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 26 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-02-03 | Kumar Ramesh President and CEO | Exercise or conversion | +20,000 | $6.00 | $120K | 296,500 |
| 2014-02-03 | Kumar Ramesh President and CEO | Sale | −20,000 | $15.07 | $301K | 276,500 |
| 2014-02-03 | Kumar Ramesh President and CEO | Exercise or conversion · Stock Option (right to buy) | −20,000 | 50,282 | ||
| 2014-01-31 | Kumar Ramesh President and CEO | Exercise or conversion | +20,000 | $6.00 | $120K | 296,500 |
| 2014-01-31 | Kumar Ramesh President and CEO | Sale | −20,000 | $15.03 | $301K | 276,500 |
| 2014-01-31 | Kumar Ramesh President and CEO | Exercise or conversion · Stock Option (right to buy) | −20,000 | 70,282 | ||
| 2014-01-30 | Kumar Ramesh President and CEO | Exercise or conversion | +5,256 | $2.67 | $14K | 281,756 |
| 2014-01-30 | Kumar Ramesh President and CEO | Exercise or conversion | +14,744 | $6.00 | $88K | 296,500 |
| 2014-01-30 | Kumar Ramesh President and CEO | Sale | −20,000 | $15.05 | $301K | 276,500 |
| 2014-01-30 | Kumar Ramesh President and CEO | Exercise or conversion · Stock Option (right to buy) | −5,256 | 0 | ||
| 2014-01-30 | Kumar Ramesh President and CEO | Exercise or conversion · Stock Option (right to buy) | −14,744 | 90,282 | ||
| 2014-01-27 | Hoffman Michael B Director | Purchase | +25,589 | $11.86 | $303K | 4,374,795 |
| 2014-01-27 | Michael & Jane Hoffman 2013 Descendants 10% owner | Purchase | +25,589 | $11.86 | $303K | 4,374,795 |
| 2014-01-24 | Hoffman Michael B Director | Purchase | +31,706 | $11.96 | $379K | 4,349,206 |
| 2014-01-24 | Michael & Jane Hoffman 2013 Descendants 10% owner | Purchase | +31,706 | $11.96 | $379K | 4,349,206 |
| 2013-12-20 | Kumar Ramesh President and CEO | Grant or award · Stock Option (right to purchase) | +135,000 | 135,000 | ||
| 2013-12-20 | BANSAL AJAY Chief Financial Officer | Grant or award · Stock Option (right to purchase) | +65,000 | 65,000 | ||
| 2013-12-20 | MCKEARN THOMAS J President, R&D | Grant or award · Stock Option (right to purchase) | +72,000 | 72,000 | ||
| 2013-12-20 | Altland James SVP, Finance & Corp. Develop. | Grant or award · Stock Option (right to purchase) | +12,000 | 12,000 | ||
| 2013-12-19 | Reddy E Premkumar Director | Exercise or conversion | +32,036 | $1.33 | $43K | 1,310,754 |
Page 22 of 23 · 449 trades